返回 Agenda
Session 8: Artificial Intelligence and Machine Learning Use in Patient Safety
Session Chair(s)
Jeremy Jokinen, PhD, MS
Vice President and Head, Safety Evidence and Sciences
Bristol-Myers Squibb Company, United States
Examine the uses of machine learning and artificial intelligence in safety organizations globally. Both industry and regulatory perspectives will be included. Speakers will discuss applications in safety operations, surveillance (including literature surveillance) as well as topics related to regulation and updates from the AI/ML CIOMS working group.
Learning Objective : At the conclusion of this session, participants should be able to:
- Describe recent advances in the use of AI/ML with respect to safety surveillance
- Determine the applicability of the use of AI/ML in your own organization
- Recognize the progress of cross-industry working groups to increase understanding and contextualize the use of AI/ML in pharmacovigilance
Speaker(s)
How ML and Pharmacovigilance Interrelate Currently and How Symbiotic Progress Should Enable Real PV2.0
Andrew Bate, PhD, MA
GlaxoSmithKline, United Kingdom
Vice President, Head of Safety Innovation and Analytics
Adoption of AI for Adverse Event Recognition from Unstructured Data
Nicole Duarte Vigar Baker, PhD
Biologit, Ireland
CEO
Next-Generation Pharmacovigilance Analytics – Clustering and Semantic Representations of Adverse Events
Niklas Noren, PhD, MSc
Uppsala Monitoring Centre (UMC) , Sweden
Chief Science Officer
Regulating ML; How Precise Should We Be? A Perspective from the MHRA
Phil Tregunno
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Deputy Director - Patient Safety Monitoring